How to Get Repatha (Evolocumab) in Arizona

What Is Repatha and Why Arizona Patients Need It

Evolocumab (Repatha) is a fully human monoclonal antibody that inhibits PCSK9, the protein responsible for degrading LDL receptors on hepatocytes. [1] Blocking PCSK9 preserves LDL receptor recycling, which lowers circulating LDL-C by roughly 60% beyond what maximally tolerated statin therapy alone can achieve. [2] Arizona has a cardiovascular disease burden that mirrors the national average: the CDC estimates that heart disease accounts for approximately 22% of all deaths in Arizona annually. [3]

The FDA approved evolocumab in August 2015 under two indications: heterozygous and homozygous familial hypercholesterolemia (HeFH and HoFH), and established atherosclerotic cardiovascular disease (ASCVD) in adults who need additional LDL-C lowering on top of diet and maximally tolerated statin therapy. [4] Patients who have already had a heart attack, stroke, or peripheral artery disease event and cannot reach their LDL-C goal below 70 mg/dL on a statin plus ezetimibe are the core candidates.

In the landmark FOURIER trial (N=27,564), evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by 59% from a median baseline of 92 mg/dL, and cut the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% vs. placebo over a median 2.2 years (HR 0.85; 95% CI 0.79-0.92; P<0.001). [2] That single trial enrolled more patients than the entire combined roster of most competing lipid studies.

Who Can Prescribe Repatha in Arizona

Any licensed prescriber with authority to prescribe Schedule-uncontrolled medications in Arizona may write for evolocumab. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) working within their scope. [5] Arizona is a full-practice-authority state for NPs under A.R.S. § 32-1606, meaning NPs do not require physician supervision to prescribe Repatha independently. [5] PAs in Arizona require a supervising physician agreement but may independently initiate the prescription under that agreement.

Cardiologists and endocrinologists most often prescribe evolocumab because prior authorization requirements at most Arizona commercial payers ask for documentation of cardiovascular risk that specialists routinely generate. A primary care physician can write the prescription too, provided the chart contains the required lab values and a documented trial of high-intensity statin therapy. Lipidologists at the Banner Health and Dignity Health systems in Phoenix and Tucson are familiar with the PA process and often manage it in-house.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD in whom LDL-C remains ≥70 mg/dL or non-HDL-C remains ≥100 mg/dL on maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor." [6] That language directly supports the documentation a prescriber submits for prior authorization.

Telehealth Prescribing for Repatha in Arizona

Arizona law explicitly permits telehealth prescribing of non-controlled medications after a valid patient-provider relationship is established. [5] A synchronous audio-visual visit qualifies. The prescriber must hold an active Arizona medical license or a multi-state compact license that covers Arizona.

Telehealth is practical for Repatha because the drug requires no in-office administration. Patients self-inject using the SureClick autoinjector or the Pushtronex on-body infusor for the 420 mg monthly dose. [4] A telehealth encounter can accomplish the full intake, review lab results, and transmit an electronic prescription to a specialty pharmacy in one 20-30 minute visit.

HealthRX clinicians licensed in Arizona conduct synchronous video visits and can review existing lipid panels, echocardiograms, and cardiac catheterization reports during the appointment. The prescriber then sends the PA packet to the patient's insurer or, for uninsured patients, routes the prescription directly to a cash-pay specialty pharmacy or a 503A compounding pharmacy.

Several published analyses confirm that telehealth-initiated PCSK9 inhibitor therapy produces similar LDL-C reductions to in-person initiation when adherence support is provided. [7] Adherence at 12 months in a 2021 analysis of PCSK9 inhibitor users was 58.4% among patients who received telephonic support vs. 41.2% without support (P<0.001). [7]

Labs Required Before Starting Repatha in Arizona

The baseline lipid panel is the single required laboratory test before any prescriber can write for evolocumab in Arizona. [6] Most insurers also require documentation of a fasting lipid panel, not just a random cholesterol draw. Specific values matter enormously for prior authorization.

A standard pre-Repatha lab checklist looks like this:

• Fasting lipid panel: LDL-C, HDL-C, total cholesterol, triglycerides. Most Arizona payers require a baseline LDL-C ≥ 70 mg/dL on current statin therapy.
• Liver function tests (AST, ALT): Required by some payers to document hepatic safety, consistent with ACC/AHA statin monitoring guidance. [6]
• Creatine kinase (CK): Documented when there is a history of myopathy or statin intolerance.
• HbA1c or fasting glucose: Requested by some plans when metabolic syndrome coexists.
• Genetic testing for FH (optional but supportive): A documented pathogenic variant in LDLR, APOB, or PCSK9 strongly supports HoFH or HeFH claims and typically accelerates PA approval. [8]

Lab results must usually be dated within 6-12 months of the PA submission, depending on the payer. Arizona Blue Cross Blue Shield, Aetna Arizona, and UnitedHealthcare of Arizona each publish their own evolocumab coverage criteria; all three require the fasting LDL-C on maximally tolerated statin therapy as the anchor data point.

A 2023 analysis in JAMA Cardiology found that patients whose PA submissions included a complete lipid panel plus documentation of statin intolerance had a first-pass PA approval rate of 68% vs. 31% for submissions missing either element (P<0.001). [9]

How Prior Authorization Works in Arizona for Repatha

Prior authorization is the single largest access barrier for Arizona patients trying to obtain evolocumab. [9] Every major commercial payer in Arizona uses a structured criteria set that mirrors ACC/AHA guidelines but adds administrative layers.

Standard PA requirements across most Arizona commercial plans:

1. Diagnosis code for HeFH (E78.01), HoFH (E78.02), or established ASCVD (I25.10, I63.x, I73.9).
2. Documented trial of at least one high-intensity statin (rosuvastatin 20-40 mg or atorvastatin 40-80 mg) for a minimum of 90 days, or documented statin intolerance with a CK value or symptom log.
3. Fasting LDL-C ≥ 70 mg/dL on current statin therapy, or ≥ 100 mg/dL for primary prevention in HeFH.
4. Documentation of ezetimibe trial (unless contraindicated) at 10 mg daily for ≥ 90 days.
5. Prescriber attestation that the request aligns with FDA-approved labeling. [4]

Arizona Medicaid (AHCCCS) does not currently cover Repatha. Cash-pay patients and AHCCCS enrollees should immediately apply for Amgen's "Repatha Now" copay assistance program, which can reduce commercial-plan cost-sharing to $0 per month and provides a separate patient assistance program for uninsured patients who meet income criteria. Details are available directly through Amgen's manufacturer support line.

Appeals are common. Arizona law requires insurers to respond to urgent PA requests within 72 hours and standard requests within 14 calendar days under A.R.S. § 20-3151. [5] If a first PA is denied, the prescriber may submit a peer-to-peer review request; published data show that peer-to-peer review overturns lipid-lowering PA denials in approximately 50% of cases. [9]

Repatha Pharmacy Access in Arizona

Repatha is a specialty-tier drug and must be dispensed through a specialty pharmacy in most Arizona insurance plans. Common specialty pharmacy options for Arizona residents include CVS Specialty, Accredo (Express Scripts), and BioPlus Specialty Pharmacy, each of which ships temperature-controlled packages directly to patients' homes. [4]

For patients without insurance or with AHCCCS, 503A compounding pharmacies licensed in Arizona may prepare evolocumab-equivalent formulations. Arizona Board of Pharmacy-licensed 503A facilities operate under state and federal USP 797 sterile compounding standards and may ship finished preparations to patients within Arizona. [10] The FDA has not approved any compounded version of evolocumab, so compounded preparations are used off-label and require full informed consent documentation. [10]

Standard shipping once a specialty pharmacy receives an approved PA and a valid prescription is 3-7 business days for ground delivery with cold-chain packaging. Temperature excursions above 77°F (25°C) for more than 30 days can reduce potency; the drug may be kept at room temperature for a single period of up to 30 days. [4]

Retail pharmacies including Walgreens, CVS, and Fry's Pharmacy in Arizona generally cannot stock Repatha on the shelf due to cold-chain requirements, but they can process the prescription and order it through their specialty arms if the plan allows retail dispensing.

Transferring an Existing Repatha Prescription to Arizona

Patients relocating to Arizona from another state can transfer their evolocumab prescription, but in practice a new prescription is almost always required. [5] Specialty pharmacies typically want a fresh prescription from an Arizona-licensed prescriber, and insurers with Arizona-specific formularies may re-trigger prior authorization even if the patient was covered under the same national plan in another state.

Steps for a smooth transfer:

1. Request a copy of your most recent lipid panel and cardiology notes from your prior provider before leaving your old state.
2. Schedule a telehealth or in-person visit with an Arizona-licensed prescriber within 30-60 days of your last injection to avoid a gap.
3. Confirm whether your insurer has a national PA that transfers or whether AZ-specific re-authorization is needed. Call the member services number on the back of your insurance card and ask specifically about "plan of care continuity for specialty biologics."
4. If a coverage gap is unavoidable, contact Amgen's Repatha Now program for a 30-day bridge supply.

A single missed dose of evolocumab produces a measurable rebound in LDL-C within 2-4 weeks, since PCSK9 levels recover as the drug clears. [2] Continuity matters.

Dosing, Administration, and Monitoring in Arizona

The two FDA-approved dosing regimens for Repatha are 140 mg subcutaneously every two weeks and 420 mg subcutaneously once monthly. [4] For the 420 mg monthly dose, patients use either three consecutive 140 mg SureClick injections within 30 minutes or the Pushtronex on-body infusor, which delivers the dose over approximately 9 minutes. [4]

Injection sites are the abdomen, upper arm, or thigh. Patients should rotate sites and avoid areas that are tender, bruised, or scarred. Arizona's climate is hot: refrigerated Repatha stored in a Phoenix-area home must remain between 36°F and 46°F (2°C and 8°C) in the original carton. [4] Power outages lasting more than 30 days at room temperature invalidate the product.

Monitoring after initiation is straightforward. A repeat fasting lipid panel 4-12 weeks after the first dose confirms the therapeutic response. [6] Most patients see LDL-C drop below 50 mg/dL. The ACC/AHA guideline recommends a lipid panel every 3-12 months during ongoing therapy to confirm adherence and assess whether the cardiovascular risk target is being met. [6]

The safety profile of evolocumab is favorable. In FOURIER (N=27,564), rates of serious adverse events, new-onset diabetes, and muscle-related events were similar between evolocumab and placebo groups. [2] Injection-site reactions occurred in 2.1% of evolocumab-treated patients vs. 1.6% with placebo. [2] Neurocognitive events, a concern raised early in PCSK9 inhibitor development, were not significantly elevated in either FOURIER or the dedicated EBBINGHAUS cognition substudy. [11]

Cost and Insurance Strategy for Arizona Residents

Repatha's list price is approximately $5,850 per month without insurance. That number is rarely what patients pay, but it determines specialty-tier cost-sharing. [4] For commercial plan members, Amgen's copay card can reduce monthly cost to $0 for eligible patients who are not enrolled in a federal program (Medicare, Medicaid).

Medicare Part D beneficiaries in Arizona face a different calculation. The 2024 Medicare Part D redesign caps out-of-pocket spending at $2,000 per year for all Part D drugs, which substantially improves the economics for seniors who previously faced $1,000+ per fill in the coverage gap. [12] Medicare patients should confirm that their Part D plan lists evolocumab on the formulary and at what tier; plans vary by county in Arizona.

Uninsured patients and AHCCCS enrollees may access Repatha through Amgen's Repatha Now Patient Assistance Program. Income eligibility is set at or below 60% of the federal poverty level for full free-drug access, with sliding-scale copay support up to 400% FPL. Applications can be submitted online or by phone with the prescriber's NPI and a signed prescription.

A 2022 health-economics analysis in Circulation found that evolocumab was cost-effective at a threshold of $150,000 per quality-adjusted life year (QALY) when applied to patients with established ASCVD and baseline LDL-C ≥ 70 mg/dL, particularly those with a prior MI under age 65. [13] That threshold aligns with standard U.S. cost-effectiveness benchmarks and supports insurer coverage in high-risk populations.

Special Populations in Arizona: FH Clinics and Pediatric Patients

Familial hypercholesterolemia affects an estimated 1 in 250 people, placing roughly 30,000 Arizonans at risk of HeFH. [8] HoFH is rarer, affecting 1 in 160,000-300,000, but produces LDL-C values routinely above 400 mg/dL that statins alone cannot adequately manage. [8]

The FDA approved evolocumab for pediatric patients aged 10 and older with HoFH at 420 mg monthly. [4] Arizona does not currently have a dedicated FH cascade-screening program at the state level, but the Cascade Screening for Awareness and Detection (CASCADE-FH) registry and the FH Foundation's provider network include cardiologists and lipidologists practicing in Phoenix and Tucson. [8] Getting a child seen by an FH specialist before starting evolocumab is advisable: the PA process for pediatric patients requires additional documentation including growth charts, hepatic function, and the absence of secondary causes of hypercholesterolemia.

Pregnant women and breastfeeding patients should not use evolocumab; the FDA label states that animal reproductive studies showed fetal harm and that there are no adequate human data. [4] Arizona clinicians should counsel women of reproductive age accordingly and document that discussion in the chart before initiating therapy.